Institute for Wealth Management LLC. Purchases New Position in Natera, Inc. (NASDAQ:NTRA)

Institute for Wealth Management LLC. acquired a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,864 shares of the medical research company's stock, valued at approximately $264,000.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Natera by 7.7% during the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after buying an additional 879,463 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Natera by 134.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after acquiring an additional 3,871,862 shares during the period. JPMorgan Chase & Co. grew its position in shares of Natera by 43.7% during the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock valued at $1,060,836,000 after acquiring an additional 2,036,396 shares during the period. Wellington Management Group LLP increased its stake in shares of Natera by 15.7% in the 4th quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock valued at $512,898,000 after purchasing an additional 439,778 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Natera by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock worth $355,809,000 after purchasing an additional 142,201 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 9,563 shares of the stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $1,323,614.83. Following the transaction, the chief executive officer now owns 212,541 shares of the company's stock, valued at approximately $29,417,799.81. This represents a 4.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 2,562 shares of Natera stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $138.41, for a total value of $354,606.42. Following the completion of the transaction, the chief financial officer now directly owns 75,557 shares of the company's stock, valued at approximately $10,457,844.37. This represents a 3.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 59,755 shares of company stock valued at $8,898,589 over the last 90 days. 7.60% of the stock is owned by company insiders.

Analysts Set New Price Targets

NTRA has been the topic of several research analyst reports. Morgan Stanley raised their price objective on Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Piper Sandler lifted their price target on shares of Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Thursday, May 15th. UBS Group upped their price objective on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Royal Bank Of Canada started coverage on shares of Natera in a research report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price on the stock. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $180.00 price objective on shares of Natera in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $184.63.

Natera Stock Up 0.9%

Shares of Natera stock traded up $1.50 during mid-day trading on Tuesday, hitting $171.87. The stock had a trading volume of 935,378 shares, compared to its average volume of 1,408,278. Natera, Inc. has a 12-month low of $92.14 and a 12-month high of $183.00. The firm has a market cap of $23.47 billion, a P/E ratio of -116.92 and a beta of 1.74. The firm has a 50-day moving average of $157.44 and a two-hundred day moving average of $158.45.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The company's quarterly revenue was up 36.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.56) EPS. Sell-side analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.